"Novo Nordisk cut prices on Wegovy and Ozempic by up to 48% in India at the start of April 2026, a direct response to low-cost generic semaglutide flooding the market."
"Shares are trading at around $36.98, down 43% over the past year and near their 52-week low of $35.12."
"By April 1 and 2, r/investing had taken over, with the dominant post asking 'Is Novo Nordisk the new 'Intel'? (When high ROE meets a falling knife).'"
Novo Nordisk reduced prices on Wegovy and Ozempic by up to 48% in India in April 2026, responding to the influx of low-cost generic semaglutide. The company's shares have fallen 43% over the past year, trading around $36.98. Recent FDA approvals for Wegovy HD and Awiqli highlight an active pipeline, but financial pressures remain. Sentiment on Reddit shifted from bullish to bearish, with significant engagement on posts discussing the company's challenges and market position.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]